Patient characteristics
| Characteristic . | No. . | % . | Median . | Range . |
|---|---|---|---|---|
| Total no. of patients | 56 | |||
| Male sex | 28 | 50 | ||
| Age, y | 53 | 2-68 | ||
| Donor type | ||||
| Matched sibling | 20 | 36 | ||
| Haploidentical | 1 | 2 | ||
| Matched unrelated donor | 4 | 7 | ||
| Single-unit umbilical cord blood | 8 | 14 | ||
| Double-unit umbilical cord blood | 23 | 41 | ||
| Diagnosis | ||||
| AA | 1 | 2 | ||
| ALL/AML/MDS | 39 | 70 | ||
| CML | 2 | 4 | ||
| NHL/HL | 8 | 14 | ||
| MPN/MM | 6 | 11 | ||
| Disease risk index | ||||
| Low | 11 | 20 | ||
| Intermediate | 34 | 61 | ||
| High | 7 | 13 | ||
| Very high | 3 | 5 | ||
| Nonmalignant | 1 | 2 | ||
| Conditioning | ||||
| MAC/TBI | 25 | 45 | ||
| MAC/no TBI | 4 | 7 | ||
| RIC | 27 | 48 | ||
| GVHD prophylaxis | ||||
| Cyclosporine A/methotrexate | 10 | 18 | ||
| Cyclosporine A/mycophenolate mofetil | 35 | 63 | ||
| Sirolimus/mycophenolate mofetil | 7 | 13 | ||
| Other | 4 | 7 | ||
| Karnofsky score | ||||
| ≤80 | 11 | 20 | ||
| >80 | 45 | 80 | ||
| HCT-specific comorbidity index | ||||
| Low risk | 16 | 29 | ||
| Intermediate risk | 19 | 34 | ||
| High risk | 20 | 36 | ||
| Missing | 1 | 2 | ||
| Total nucleated cell count × 108/kg | 0.8 | 0.2-18.6 | ||
| CD34 × 106/kg | 1.4 | 0.02-21.8 | ||
| CD3 × 108/kg | 0.1 | 0.02-0.9 |
| Characteristic . | No. . | % . | Median . | Range . |
|---|---|---|---|---|
| Total no. of patients | 56 | |||
| Male sex | 28 | 50 | ||
| Age, y | 53 | 2-68 | ||
| Donor type | ||||
| Matched sibling | 20 | 36 | ||
| Haploidentical | 1 | 2 | ||
| Matched unrelated donor | 4 | 7 | ||
| Single-unit umbilical cord blood | 8 | 14 | ||
| Double-unit umbilical cord blood | 23 | 41 | ||
| Diagnosis | ||||
| AA | 1 | 2 | ||
| ALL/AML/MDS | 39 | 70 | ||
| CML | 2 | 4 | ||
| NHL/HL | 8 | 14 | ||
| MPN/MM | 6 | 11 | ||
| Disease risk index | ||||
| Low | 11 | 20 | ||
| Intermediate | 34 | 61 | ||
| High | 7 | 13 | ||
| Very high | 3 | 5 | ||
| Nonmalignant | 1 | 2 | ||
| Conditioning | ||||
| MAC/TBI | 25 | 45 | ||
| MAC/no TBI | 4 | 7 | ||
| RIC | 27 | 48 | ||
| GVHD prophylaxis | ||||
| Cyclosporine A/methotrexate | 10 | 18 | ||
| Cyclosporine A/mycophenolate mofetil | 35 | 63 | ||
| Sirolimus/mycophenolate mofetil | 7 | 13 | ||
| Other | 4 | 7 | ||
| Karnofsky score | ||||
| ≤80 | 11 | 20 | ||
| >80 | 45 | 80 | ||
| HCT-specific comorbidity index | ||||
| Low risk | 16 | 29 | ||
| Intermediate risk | 19 | 34 | ||
| High risk | 20 | 36 | ||
| Missing | 1 | 2 | ||
| Total nucleated cell count × 108/kg | 0.8 | 0.2-18.6 | ||
| CD34 × 106/kg | 1.4 | 0.02-21.8 | ||
| CD3 × 108/kg | 0.1 | 0.02-0.9 |
AA, aplastic anemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; HL, Hodgkin lymphoma; MDS, myelodysplastic syndrome; MM multiple myeloma; MPN, myeloproliferative neoplasm; NHL, non-Hodgkin lymphoma.